For diagnostics companies
Hyperdrive lab testing data shows testing volume and test adoption trends by indication, biomarker, method and region, resolved to the ordering provider. Forecasts and market sizing start from observed testing rather than estimates.
6M+
Lab test orders and results a year
3.8M+
New patient cases a year, across indications
18,889
US laboratories in the Lab Directory
Test adoption forecasts usually start from claims, published estimates and survey data. Claims arrive months after the order, and they rarely show which method was used or which provider ordered the test.
Adoption also moves unevenly. A new test can take hold at a few academic centers well before it reaches community practice, and a national number hides where the shift is happening.
01
Testing volume by indication, biomarker and method over time, from pathology and genomics reference labs in the Hyperdrive Lab Data Network.
02
Which providers and sites of care are ordering a test or method, and how that changes quarter to quarter, resolved to the ordering provider.
03
New patient cases and testing volume by region, care setting and provider segment, for internal forecasting and planning.
04
For sales teams, sales enablement shows what each lab bills Medicare Part B by methodology and CPT code, and the pathologists in each market.
De-identified lab testing data from pathology and genomics reference labs in the Hyperdrive Lab Data Network, resolved to the ordering provider: testing volume, methods and test adoption by indication, biomarker, provider and region.
As prospective weekly data with lookbacks, or as custom analyses built around a specific test, indication or forecasting question.
All aggregated data from the Lab Data Network is de-identified under the HIPAA Safe Harbor method or by Expert Determination before it is used in any Hyperdrive product.
Yes. Voyager, Hyperdrive’s sales enablement software, shows what each physician group, hospital and laboratory bills Medicare Part B for lab testing by methodology and CPT code, and lets reps search pathologists by specialty and location.
Tell us the test, indication or biomarker and the geography. We will walk through the testing volume and adoption trend behind it, on data you can check.